Faculty Collaboration Database

Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod 1987 Feb;6(1):20-7

Date

02/01/1987

Pubmed ID

3104544

Scopus ID

2-s2.0-0023156669 (requires institutional sign-in at Scopus site)   78 Citations

Abstract

Thirty-three patients with metastatic renal cell carcinoma were treated with recombinant human interferon gamma (rIFN gamma) in two sequential, nonrandomized phase II studies. Fifteen patients received rIFN gamma by daily i.m. injection in doses ranging from 0.25 to 1.0 mg/m2, and 18 patients received it by daily continuous i.v. infusion in doses ranging from 0.01 to 0.05 mg/m2. Partial remissions were achieved by one of 14 (7%) evaluable patients in the i.m. study and in one of 16 in the i.v. study (6%). The incidence of clinical toxicity was similar for both studies. Toxicity was severe in patients receiving rIFN gamma by the i.m. route at 1.0 mg/m2 and by the i.v. route at 0.05 mg/m2. Toxicity includes constitutional symptoms (fatigue, anorexia, weight loss), leukopenia, abnormalities in liver function tests, and hypertriglyceridemia. At the doses and schedules used, rIFN gamma had minimal therapeutic activity as a single agent in metastatic renal cell carcinoma.

Author List

Quesada JR, Kurzrock R, Sherwin SA, Gutterman JU

Author

Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Carcinoma, Renal Cell
Drug Evaluation
Female
Humans
Infusions, Intravenous
Injections, Intramuscular
Interferon-gamma
Kidney Neoplasms
Male
Recombinant Proteins